Skip to content

Coronary Aspiration Catheter Clinical Trial

A Prospective, Multicenter, Randomized Controlled, Noninferiority Clinical Trial Evaluating the Efficacy and Safety of an Aspiration Catheter in Patients Undergoing PCI for Acute ST-Segment Elevation Myocardial Infarction (STEMI)

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06951724
Enrollment
144
Registered
2025-04-30
Start date
2025-02-20
Completion date
2026-06-30
Last updated
2025-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST-segment Elevation Myocardial Infarction (STEMI)

Brief summary

To evaluation of the efficacy and safety of an aspiration catheter in patients undergoing PCI for acute ST-segment elevation myocardial infarction (STEMI).

Interventions

Thrombus aspiration using Aspiration Catheter

DEVICEExport Advance Aspiration Catheter

Thrombus aspiration using Export Advance Aspiration Catheter

Sponsors

BrosMed Medical Co., Ltd
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

\- General inclusion criteria 1. Age 18-80 years old (inclusive); 2. Clinical diagnosis of acute ST-segment elevation myocardial infarction (STEMI) within 24 hours of the onset of the disease (where ST-segment elevation is defined as ST-segment elevation of ≥1mm or 0.1mV in 2 or more consecutive leads of the 12-lead ECG); 3. Voluntary participation and signed written informed consent. Imaging Inclusion Criteria 4. DSA image showed that the target lesion was in situ coronary artery lesion; 5. Target vessel TIMI thrombus load classification ≥ grade 3 and TIMI flow classification ≤ grade 1;

Exclusion criteria

\- General

Design outcomes

Primary

MeasureTime frameDescription
The rate of TIMI flow grad 3 after PCIImmediately after procedureDefined as the percentage of subjects with TIMI flow graded 3 after PCI.

Secondary

MeasureTime frameDescription
MBGImmediately after procedureMBG (Myocardial Blush Grade) after coronary thrombus aspiration using either the test device or the control device. There are 4 levels of MBG. Grades range from 0 and up to 3, with higher grades being better.
TIMI Thrombus GradeImmediately after procedureTIMI Thrombus Grade after coronary thrombus aspiration using either the test device or the control device. There are 6 levels of MBG. Grades range from 0 and up to 5, with higher grades being worse.
STR(ST-segment resolution) at 90 minutesDay 0The index of change in the highest level of ST-segment elevation relative to the highest level of preoperative ST-segment elevation was assessed on the basis of electrocardiographic at 90 min ± 30 min after PCI.
TIMI flow after PCIImmediately after procedureTarget vessel TIMI (Thrombolysis In Myocardial Infarction) flow grad after PCI, after completion of of coronary thrombus using the test device or control device to complete thrombus aspiration
Device technical success rateImmediately after procedureThe test device or control device is able to successfully pass through all target lesions, complete thrombus aspiration, and successfully withdraw without complications relate to the procedure during thrombus aspiration, and TIMI flow grade 3 in the immediately after PCI.
MACE30-day follow-up after procedureMACE includes cardiovascular death, recurrent myocardial infarction, all strokes, and target vessel revascularization (TVR)
AE and SAE30-day follow-up after procedureIncidence of all adverse events, serious adverse events in both groups
Thrombus aspiration time and number of aspirationsImmediately after procedureRecord and compare the total thrombus aspiration time and number of aspirations in both groups.

Countries

China

Contacts

Primary ContactGe Junpo, Ph.D
ge.junbo@zs-hospital.sh.cn021-31587851

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026